Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion ...
Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed after the company reported weaker-than-expected first-quarter 2025 results, ...
Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs.
Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Never heard of it? Don't sweat it. Plenty of people haven't. Its $2 billion market capitalization doesn't turn many heads. Losses that are persistently greater than its scant revenue don't draw a ...
11don MSN
Recursion Pharmaceuticals just hit a 52-week low. Is this former Nvidia holding a smart buy now?
The stock looks cheap, but appearances can be deceiving.
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Stream NBC 5 for free, 24/7, wherever you are. In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results